Integrated analysis of preclinical data to support the design of the first in man study of LY2181308, a second generation antisense oligonucleotide

British Journal of Clinical Pharmacology

Volumn 71, Issue 3, 2011, Pages 416-428

  Callies, Sophie ^a   André, Valérie ^a   Patel, Bharvin ^a   Waters, David ^a   Francis, Paul ^a   Burgess, Michael ^a   Lahn, Michael ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Antisense oligonucleotide; Dose prediction; Model

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; LY 2181308; MESSENGER RNA; SURVIVIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CANCER INHIBITION; CREATININE CLEARANCE; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DESIGN; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TISSUE LEVEL; DRUG UPTAKE; EXPERIMENTAL MONKEY; HUMAN; HUMAN TISSUE; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUGS, INVESTIGATIONAL; HAPLORHINI; HUMANS; MICE; MODELS, BIOLOGICAL; NEOPLASMS; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; RESEARCH DESIGN; RNA, MESSENGER;

EID: 79251643216     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03836.x     Document Type: Article

References (23)

1. Simeoni M, Magni P, Cammia C, De Nicolao G, Croci V, Pesenti E, Germani M, Poggesi I, Maurizio Rocchetti M. Predictive pharmacokinetic-pharmacodynamic modeling of tumour growth kinetics in xenograft models after administration of anticancer agents. Cancer Res 2004; 64: 1094-101.
2. Zhang L, Sinha V, Forgue ST, Callies S, Ni L, Peck R, Allerheiligen SRB. Model-based drug development: the road to quantitative pharmacology. J Pharmacokinet Pharmacodyn 2006; 33: 369-93.
3. Patel BKR, Carrasco RA, Stamm NB, Marcusson E, Sandusky G, Iversen P. Antisense inhibition of survivin expression as a cancer therapeutic. (Submitted Cancer Research).
4. Li F, Brattain MG. Role of the survivin gene in pathophysiology. Am J Pathol 2006; 169: 1-11.
5. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003; 3: 46-54.
6. Geary RS, Yu RZ, Watanabe T, Henry SP, Hardee GE, Chappell A, Matson J, Sasmor H, Cummins L, Levin AA. Pharmacokinetics of a tumour necrosis factor-alpha phosphorothioate 2′-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species. Drug Metab Dispos 2003; 31: 1419-28.
7. Saleem A, Ranson M, Callies S, Lahn M, Prenant C, Brown G, Matthews JC, Dence CS, McMahon A, Price P. Microdosing imaging pharmacokinetic (PK) study of the antisense oligonucleotide (ASO) to survivin (LY2181308) using positron emission tomography (PET): a novel paradigm in clinical drug development. J Clin Oncol 2009; 27: 15S.
8. Talbot DC, Davies J, Callies S, Andre V, Lahn M, Ang J, De Bono JS, Ranson M. First human dose study evaluating safety and pharmacokinetics of LY2181308, an antisense oligonucleotide designed to inhibit survivin. J Clin Oncol 2008; 26: 20S.
9. Talbot DC, Davies J, Olsen A, Andre V, Lahn M, Powell E, Kadam S, de Bono J, McHugh P, Ranson M. Pharmacodynamic (PD) evaluation of LY2181308 in patients with metastatic malignancies. J Clin Oncol 2009; 27: 15S.
10. Knudsen BS. Evaluation of the branched-chain DNA assay for measurement of RNA in formalin-fixed tissues. J Mol Diagn 2008; 10: 169-76.
11. Bacus S, Flowers JL, Press MF, Bacus JW, McCarty KS, Jr. The evaluation of estrogen receptors in primary breast carcinoma by computer-assisted image analysis. Am J Clin Pathol 1988; 90: 233-9.
12. Boeckmann AJ, Sheiner LB, Beal SL. NONMEM Users Guide. NONMEM Project Group. San Francisco CA: University of California, 1994.
13. Sheiner LB. Population pharmacokinetics: the population approach to pharmacokinetic data analysis: rational and standard data analysis methods. Drug Metab Rev 1984; 15: 153-71.
14. Sun H, Fadiran EO, Jones CD, Lesko L. Population pharmacokinetics - a regulatory perspective. Clin Pharmacokinet 1999; 37: 41-51.
15. Wade JR, Beal SL, Sambol NC. Interaction between structural, statistical and covariate models in population pharmacokinetic analysis. J Pharmacokinet Biopharm 1994; 22: 165-77.
16. Yu RZ, Geary RS, Leeds JM, Watanabe T. Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate oligonucleotide targeting human Ha-ras mRNA in mouse and monkey. J Pharm Sci 2001; 90: 182-93.
17. Herrington WG, Talbot D, Lahn MM, Brandt JT, Callies S, Nagle R, Winearls CG, Roberts ISD. Long-term administration of the survivin mRNA-targeted antisense oligonucleotide LY2181308 causing renal injury. Am J Kidney Dis 2010 (in press).
18. Johnson JI, Decker S, Zaharevitz D, Rubinstein LV. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 2001; 84: 1424-31.
19. Kamp A. What's wrong with our cancer models? Nat Rev Drug Discov 2005; 4: 161-5.
20. Jason TL, Koropatnick J, Berg RW. Toxicology of antisense therapeutics. Toxicol Appl Pharmacol 2004; 201: 66-83.
21. Mathijssen Ron HJ, De Jong FA, Loos WJ, Van Der Bol JM, Verweij J, Sparreboom A. Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference? Oncologist 2007; 12: 913-23.
22. Chi KN, Eisenhauer E, Fazli L, Jones EC, Goldenberg SL, Powers J, Tu D, Gleave ME. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 2005; 97: 1287-96.
23. Dean E, Jodrell D, Connolly K, Danson S, Jolivet J, Durkin J, Morris S, Jowle D, Ward T, Cummings J, Dickinson G, Aarons L, Lacasse E, Robson L, Dive C, Ranson M. Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer. J Clin Oncol 2009; 27: 1660-6.